Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03729804 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)

Study acronym: (COBRA)
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv12
  2. Primary completion date: Dec 28, 2025 to Dec 28, 2026v11
  3. Primary completion date: Jul 2025 to Dec 28, 2025
    • Study completion date: Jul 24, 2026 to Dec 28, 2026
    v10
  4. Primary completion date: Dec 24, 2024 to Jul 2025
    • Study completion date: Dec 24, 2024 to Jul 24, 2026
    v9
  5. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v8
Show 6 earlier versionsHide 6 earlier versions
  1. Re-verified, no change to tracked fieldsv7
  2. Primary completion date: Dec 24, 2022 to Dec 24, 2024v6
  3. Primary completion date: Dec 24, 2021 to Dec 24, 2022
    • Study completion date: Dec 24, 2023 to Dec 24, 2024
    • Site contact updated
    v5
  4. Re-verified, no change to tracked fieldsv4
  5. Site contact updatedv3
  6. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Dec 24, 2018 to May 7, 2019
    • Site details revised
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a randomized multicenter study that will compare two treatment regimens (Kyprolis, Revlimid, dexamethasone -KRD vs. Velcade, Revlimid, dexamethasone -VRD) for patients with newly diagnosed multiple myeloma.
Trial Details
NCT Number NCT03729804
Lead Sponsor University of Chicago
Conditions
(from sponsor)		 Multiple Myeloma
Related terms Multiple Myeloma
Enrollment 250 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov